CA2697988A1 - Method of predicting drug-induced phospholipidosis - Google Patents

Method of predicting drug-induced phospholipidosis Download PDF

Info

Publication number
CA2697988A1
CA2697988A1 CA2697988A CA2697988A CA2697988A1 CA 2697988 A1 CA2697988 A1 CA 2697988A1 CA 2697988 A CA2697988 A CA 2697988A CA 2697988 A CA2697988 A CA 2697988A CA 2697988 A1 CA2697988 A1 CA 2697988A1
Authority
CA
Canada
Prior art keywords
drug
cell
cells
intracellular
test compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2697988A
Other languages
English (en)
French (fr)
Inventor
Yoshitaka Tanaka
Kazuhiko Ikeda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyushu University NUC
Astellas Pharma Inc
Original Assignee
Astellas Pharma Inc.
Yoshitaka Tanaka
Kazuhiko Ikeda
Kyushu University, National University Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc., Yoshitaka Tanaka, Kazuhiko Ikeda, Kyushu University, National University Corporation filed Critical Astellas Pharma Inc.
Publication of CA2697988A1 publication Critical patent/CA2697988A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G01N2333/918—Carboxylic ester hydrolases (3.1.1)
    • G01N2333/92—Triglyceride splitting, e.g. by means of lipase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA2697988A 2007-10-04 2008-10-03 Method of predicting drug-induced phospholipidosis Abandoned CA2697988A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2007261125 2007-10-04
JP2007-261125 2007-10-04
PCT/JP2008/068034 WO2009044846A1 (ja) 2007-10-04 2008-10-03 薬物誘発性リン脂質症の予測方法

Publications (1)

Publication Number Publication Date
CA2697988A1 true CA2697988A1 (en) 2009-04-09

Family

ID=40526268

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2697988A Abandoned CA2697988A1 (en) 2007-10-04 2008-10-03 Method of predicting drug-induced phospholipidosis

Country Status (5)

Country Link
US (1) US20110117588A1 (ja)
EP (1) EP2194141A4 (ja)
JP (1) JP5062578B2 (ja)
CA (1) CA2697988A1 (ja)
WO (1) WO2009044846A1 (ja)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9841426B2 (en) * 2009-03-11 2017-12-12 Marker Gene Technologies, Inc Intracellular organelle peptide targeted enzyme substrates
JP5940288B2 (ja) 2011-11-30 2016-06-29 オリンパス株式会社 画像処理装置、顕微鏡システム、画像処理方法、及び画像処理プログラム
EP3624852A4 (en) * 2017-05-17 2021-03-03 Nextcea Inc. INDUCTION OF PHOSPHOLIPIDOSIS TO IMPROVE A THERAPEUTIC EFFECT
CN108929373A (zh) * 2017-05-22 2018-12-04 苏州偶领生物医药有限公司 一种共价键修饰哺乳动物atg8 同源物的方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006112947A (ja) 2004-10-15 2006-04-27 Sumitomo Chemical Co Ltd 物質が有するホスホリピドーシス誘発能力の検定方法
GB2434445A (en) * 2006-01-13 2007-07-25 Cytokinetics Inc Assay for phospholipidosis

Also Published As

Publication number Publication date
WO2009044846A1 (ja) 2009-04-09
JP5062578B2 (ja) 2012-10-31
EP2194141A1 (en) 2010-06-09
EP2194141A4 (en) 2010-10-20
JPWO2009044846A1 (ja) 2011-02-10
US20110117588A1 (en) 2011-05-19

Similar Documents

Publication Publication Date Title
Doege et al. Targeted deletion of FATP5 reveals multiple functions in liver metabolism: alterations in hepatic lipid homeostasis
Van Hoof et al. Interpretation and clinical significance of alkaline phosphatase isoenzyme patterns
Patrakka et al. Expression of nephrin in pediatric kidney diseases
Cheung et al. Marked impairment of protein tyrosine phosphatase 1B activity in adipose tissue of obese subjects with and without type 2 diabetes mellitus
JP5061194B2 (ja) Ｇｐ７３特異的自己抗体を検出するための方法およびアッセイ
Reiche et al. SORLA/SORL1 functionally interacts with SPAK to control renal activation of Na+-K+-Cl− cotransporter 2
US20210011034A1 (en) Method for predicting the risk of obesity in a subject
Dawson et al. Putative anti-muscarinic antibodies cannot be detected in patients with primary Sjogren's syndrome using conventional immunological approaches
US20110117588A1 (en) Method of predicting drug-induced phospholipidosis
JP2011503620A (ja) リン酸化脂肪酸シンターゼ及び癌
Murasawa et al. Homotypic versican G1 domain interactions enhance hyaluronan incorporation into fibrillin microfibrils
US20120180149A1 (en) Double mutant mouse and cell lines
Henriksen et al. Should biochemical markers of bone turnover be considered standard practice for safety pharmacology?
Jelinek et al. The Niemann-Pick C1 and caveolin-1 proteins interact to modulate efflux of low density lipoprotein-derived cholesterol from late endocytic compartments
Marinò et al. Circulating thyroglobulin transcytosed by thyroid cells is complexed with secretory components of its endocytic receptor megalin
US7267820B2 (en) Neurotransmission disorders
US11090310B2 (en) Methods and compositions for treating hypertriglyceridemia
Omachi et al. Role of uncoupling protein 1 in the anti-obesity effect of β3-adrenergic agonist in the dog
JP2010101880A (ja) マイクロドメイン病のバイオマーカー
EP1913396B1 (en) Method for diagnosing tumors by measuring the level of apolipoprotein a-iv
EP2823301B1 (en) Optimal gonadotropin dosage
Babiker Assessment of Thyroid Function Tests (T3, T4 & TSH) Among Down Syndrome Patients
Romano et al. Developmental differences between cation-independent and cation-dependent mannose-6-phosphate receptors in rat brain at perinatal stages
EP3568697A1 (en) Method for diagnosis of arrhythmogenic right ventricular cardiomyopathy
KR20140033365A (ko) 가용성 lr11의 면역학적 측정방법

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20140826